New hope: testing powerful drug duo to fight tough cancers
NCT ID NCT02962063
Summary
This study is testing whether adding two new immunotherapy drugs, durvalumab and tremelimumab, to standard chemotherapy and radiation is safe and effective for treating esophageal and gastroesophageal junction cancer. The trial involves 64 patients who will receive the drug combination before, during, and after their standard cancer treatments, including surgery. Researchers want to see if this approach helps eliminate more cancer cells and improves patient outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Rockville Centre
Rockville Centre, New York, 11570, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.